Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Urvi M. Parikh
Should We Fear Resistance From Tenofovir/Emtricitabine Preexposure Prophylaxis?
Current Opinion in HIV and AIDS
Virology
Oncology
Infectious Diseases
Immunology
Hematology
Related publications
Is Tenofovir/Emtricitabine Teratogenic?
Therapeutic Advances in Drug Safety
Pharmacology
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
Emtricitabine, Tenofovir, and Rilpivirine From Their Degradation Products Analysis by HPLC
International Journal of Research in Pharmaceutical Sciences
Toxicology
Pharmaceutics
Pharmacology
First-Line Antiretroviral Therapy With Efavirenz Plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison
HIV Medicine
Health Policy
Infectious Diseases
Pharmacology
Pharmacokinetic and Safety Analyses of Tenofovir and Tenofovir-Emtricitabine Vaginal Tablets in Pigtailed Macaques
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
New England Journal of Medicine
Medicine
Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir
AIDS Patient Care and STDs
Environmental
Public Health
Infectious Diseases
Occupational Health
Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
